Vet Med - Czech, 2002, 47(8):213-217 | DOI: 10.17221/5826-VETMED

Porcine pleuropneumonia: the first evaluation of field efficacy of a subunit vaccine in Croatia

B. Habrun, V. Bilič, ®. Cvetnič, A. Humski, M. Benič
Croatian Veterinary Institute, Zagreb, Croatia

A vaccine for porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae was studied in Croatia on a farm infected by agent serotypes 2 and 9. Vaccination with a commercial subunit vaccine was initiated in the second half of 1998 due to the immense economic damage caused on the farm by this disease. All prefattening and fattening pigs kept on the farm during the first three months of 1999 were allocated in two groups: vaccinated and control. In the control and vaccinated group, 226 and 35 animals (5.78% and 0.96% of the average number of prefattening and fattening pigs in control and vaccinated group), respectively, died from pleuropneumonia. The vaccine efficacy was 83.5%. Examination of the randomly selected lungs on the slaughter line revealed significant reduction in the lesions specific for the chronic form of pleuropneumonia in the vaccinated group (vaccine efficacy 78.6%). The tested vaccine significantly decreased the death rate and pulmonary lesions due to A. pleuropneumoniae.

Keywords: porcine pleuropneumonia; immunoprophylaxis; vaccine efficacy

Published: August 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Habrun B, Bilič V, Cvetnič ®, Humski A, Benič M. Porcine pleuropneumonia: the first evaluation of field efficacy of a subunit vaccine in Croatia. Vet Med - Czech. 2002;47(8):213-217. doi: 10.17221/5826-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beaudet R., McSween G., Boulay G., Rousseau P., Bisaillon J.G., Descoteaux J.P., Ruppanner R. (1994): Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination. Vet. Microbiol., 39, 71-81. Go to original source... Go to PubMed...
    2. Beck M., Van den Bosch J.F., Jongelen I.M.C.A., Loeffen P.L.W., Nielsen R., Nicolet J., Frey J. (1994): RTX toxin genotypes and phenotypes in Actinobacillus pleuropneumoniae field strains. J. Clin. Microbiol., 32, 2749-2754. Go to original source... Go to PubMed...
    3. Bhatia B., Mittal K.R., Frey J. (1991): Factors involved in immunity against Actinobacillus pleuropneumoniae in mice. Vet. Microbiol., 29, 147-158. Go to original source... Go to PubMed...
    4. Blackall P.J., Klaasen H.L., Van den Bosch H., Kuhnert P., Frey J. (2002): Proposal of a new serovar of Actinobacillus pleuropneumoniae: serovar 15. Vet. Microbiol., 84, 47-52. Go to original source... Go to PubMed...
    5. Devenish J., Rosendal S., Bosse J.T., Wilkie B.N., Johnson R. (1990): Prevalence of seroreactors to the 104kilodalton hemolysin of Actinobacillus pleuropneumoniae in swine herds. J. Clin. Microbiol., 28, 789-791. Go to original source... Go to PubMed...
    6. Fedorka Cray P.J., Stine D.L., Greenwald M.J., Gray J.T., Huether M.J., Anderson G.A. (1993): e importance of secreted virulence factors in Actinobacillus pleuropneumoniae bacterin preparation: A comparison. Vet. Microbiol., 37, 85-100. Go to original source... Go to PubMed...
    7. Frey J. (1995a): Exotoxins of Actinobacillus pleuropneumoniae. In: Donachie W. et al: Haemophilus, Actinobacillus and Pasteurella. Plenum Press, New York. 101-113. Go to original source...
    8. Frey J (1995b): Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol., 3, 257-261. Go to original source... Go to PubMed...
    9. Kobisch M., Van den Bosch J.F. (1992): Efficacy of an Actinobacillus pleuropneumoniae subunit vaccine. 12th Int. Pig Vet. Soc. Congress. e Hague, e Netherlands. Proceedings, p. 216.
    10. Inzana T.J., Ma N.J., Veit H.P. (1991): Characterisation of non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: Role of the 110 kilodalton hemolysin in virulence and immunoprotection. Microbiol. Pathol., 10, 281-296. Go to original source... Go to PubMed...
    11. Inzana T.J., Todd J., Veit H.P. (1993): Safety, stability and efficacy of noncapsulated mutans of Actinobacillus pleuropneumoniae for use in live vaccines. Infect. Immun., 61, 1682-1686. Go to original source... Go to PubMed...
    12. Martin S.W., Meek A.H., Willeberg P. (1987): Veterinary Epidemiology. Principles and methods. Iowa State University Press, Iowa, USA. 121-148.
    13. Nicolet J. (1992): Actinobacillus pleuropneumoniae. In: Leman A.D., Straw B.E., Mengeling W.L., D'Allaire D., Taylor D.J. (eds.): Diseases of Swine. Iowa State University Press, Ames, Iowa, U.S.A. 401-408.
    14. Nielsen R., omsen A.D., Vesterlund S.D. (1976): Pleuropneumonia caused by Haemophilus parahaemolyticus. An attempt to control the disease at two progeny testing stations by serological blood testing followed by removal of the seropositive animals and litter mates. Nord. Vet. Med., 28, 349-352.
    15. Sebunya T.N.K., Saunders J.R. (1983): Haemophilus pleuropneumoniae infection in swine. A review. J. Am. Vet. Med. Ass., 182, 1331-1337.
    16. Van den Bosch J.F., Jongelen I.M.C.A., Pubben A.N.B., Van Vugt F.G.A., Segers R.P.A.M. (1992): Protection induced by a trivalent A. pleuropneumoniae subunit vaccine. In: 12th Int. Pig Vet. Soc. Congress. e Hague, e Netherlands. Proceedings, p. 94.
    17. Van Overbeke I., Chiers K., Ducatelle R., Haesenbrouck F. (2001): Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of pigs vaccinated with a vaccine containing Apx toxins ant transferrin-binding proteins. J. Vet. Med. B Infect. Dis. Vet. Public. Health, 48, 15-20. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content